Therapeutics News and Research

RSS

Simvastatin linked to protection against endothelial dysfunction in diabetic rats

Almost two years ago, the diabetes arm of the Heart Protection Study, the largest-ever study using a cholesterol-lowering medication, found that diabetics who took a daily dose of the statin drug simvastatin over five years reduced the risk of a first nonlethal heart attack by 37 percent and risk of a first nonfatal or fatal stroke by 24 percent, regardless of their cholesterol or glucose levels.

3 Apr 2005

Garlic protects against severe chronic pulmonary hypertension

Small daily doses of allicin, the active metabolic in garlic, proved effective in preventing a severe form of pulmonary hypertension in rats

3 Apr 2005

REPLICor to disclose unique antiviral drug

REPLICor Inc., a privately owned biopharmaceutical company, is developing a broad spectrum antiviral drug called REP 9 which has the broadest spectrum of activity in vitro ever reported for a single chemical entity.

30 Mar 2005

Vical Incorporated issued two Canadian patents

Vical Incorporated announced today the issuance of two Canadian patents on the company's core technology, which involves direct administration of polynucleotide genetic material such as DNA or RNA.

29 Mar 2005

Discovery of gene STAT6(B) may lead to new treatments for inflammatory diseases

In a paper featured in Proceedings of the National Academy of Science (PNAS), researchers from Boston University School of Dental Medicine report the discovery of a new gene, STAT6(B), that helps regulate production of the potentially deadly tumor necrosis factor alpha (TNF-alpha) cytokine.

28 Mar 2005

Process for disposal of dying neutrophils actively linked to neutrophil production

New research identifies a critical inhibitory step that is a key component of the feedback circuit regulating the balance between neutrophil production and destruction.

23 Mar 2005

Study suggests combination therapy could stop spread, halt growth of melanomas

Researchers at Penn State College of Medicine have identified the mechanism by which the most mutated gene in melanoma, called v599EB-Raf, aids melanoma tumor development demonstrating its importance as a therapeutic target.

22 Mar 2005

pSivida intensifies research activities

Following extremely encouraging Phase IIa clinical trial results showing successful tumor regression and safety in man, nanotechnology pioneer pSivida Limited is intensifying development of its fully patented invention of nanostructured bioactive, biodegradable and biocompatible silicon (BioSilicon™) for multiple potential healthcare applications.

21 Mar 2005

African-American women with advanced endometrial cancer have more aggressive tumors than Caucasian women

In two studies of African-American women with endometrial cancer, a group of investigators from Walter Reed Army Medical Center and the National Cancer Institute has found that African-American women with advanced endometrial cancer have more aggressive tumors than Caucasian women, potentially leading to worse outcomes.

21 Mar 2005

Major milestone in identifying and creating a register of genes involved in multiple sclerosis

For the first time in this disease area, researchers at the SGI have identified 80 genes involved in the inflammatory and neuro-degenerative pathways of MS, based on a 40% genome scan comparing the genetic profile of a total of 1,800 people with MS and healthy individuals in different populations.

17 Mar 2005

Link between a critical cancer pathway and an Epstein-Barr Virus (EBV) protein

Researchers at the University of Pennsylvania School of Medicine have identified a link between a critical cancer pathway and an Epstein-Barr Virus (EBV) protein known to be expressed in a number of EBV-associated cancers.

15 Mar 2005

Novel Australian anti-cancer therapy has begun safety testing in human subjects

An international medical conference here heard that an Australian developed anti-cancer therapy based on the use of a common cold virus to control cancer cell growth has begun safety testing in human subjects.

15 Mar 2005

New cancer drug looks promising

Dr. E. Premkumar Reddy from Temple University School of Medicine and colleagues, in a study examining the effects of Plk1 inhibitor ON01910 on tumor growth in several animal models have found that a small molecule inhibitor of polo-like kinase1 (Plk1) could lead to a new avenue for targeted cancer therapy.

14 Mar 2005

Molecule called DJ-1 is likely to be involved in the generation of human tumors

Scientists have discovered that a molecule called DJ-1 is likely to be involved in the generation of human tumors through negative regulation of the well-known tumor suppressor, PTEN. The research, published in the March issue of Cancer Cell, has important implications for determining the prognosis of some human cancers, and may prove to be a suitable target for cancer therapy.

14 Mar 2005

Taiwanese biotechnology industry expected to reach US$1.9 billion in 2010

The Taiwanese biotechnology industry has started off on the right note with the introduction of several innovative biotechnology-related products and is all set to capitalize on this lead.

14 Mar 2005

ViroLogic and AstraZeneca to conduct Iressa biomarker study

ViroLogic announced today that it had entered into an agreement with AstraZeneca to conduct a cancer biomarker study with application to Iressa, AstraZeneca's selective epidermal growth factor receptor kinase inhibitor.

7 Mar 2005

Australian biotech, Bionomics acquires central nervous system (CNS) business

Exciting Australian biotech, Bionomics has announced that it has completed the acquisition of the French central nervous system (CNS) business, Neurofit.

6 Mar 2005

Definitive evidence that TRPV3 is a temperature sensor

The human brain is like a general in a bunker. Floating in its bubble of cerebrospinal fluid, it has no direct window to the outside world, so the only way for the brain to observe, comprehend, and order the body into action is to rely on information it receives.

6 Mar 2005

Novel mutation in the recently identified LRRK2 gene causes parkinsonism

Neuroscientists at Mayo Clinic in Jacksonville, Fla., leading a team of researchers in the United States and Europe, have discovered that a novel mutation in the recently identified LRRK2 gene causes parkinsonism in several North American and European families.

27 Feb 2005

Discovery could lead to the prevention, and possibly treatment of autoimmune diseases such as Type 1 diabetes

Scientists at the University of Maryland School of Medicine in Baltimore have identified a way to prevent Type I diabetes in rats that are genetically prone to develop the disease.

23 Feb 2005